Sean Doherty Net Worth

Sean Doherty biography

Sean M. Doherty J.D. serves as Independent Director of the Company. Mr. Doherty is the Executive Chair of the JDRF T1D Fund, a $100.0 million venture philanthropy fund using a cutting-edge approach to catalyze an investment market in type one diabetes. He led the concept-creation, design and capital financing of the fund, and he has driven its strategy since its inception in 2016. He served on the JDRF International Board and its Executive Committee from 2016 to 2019. He retired from his role as Managing Director of Bain Capital, LP, a private global investment firm, which he joined in 2005 as the firm’s first general counsel. He had a diverse operational and constituency management role at Bain Capital, where he led crisis management, press and external communications, government relations, branding and philanthropic initiatives and was involved in governance and capital raising. Earlier in his career he worked at Ropes & Gray LLP, and he was a law clerk to a federal district judge in Boston. Mr. Doherty received a J.D. magna cum laude from Harvard Law School and a B.A. magna cum laude in Government from Harvard College. Prior to law school, he was a Lieutenant in the U.S. Navy, in which he served on a Middle East Force frigate from 1990-94. Mr. Doherty is a member of the board of directors of IM Therapeutics. Mr. Doherty’s experience in the concept-creation and continuing strategy management of the JDRF T1D Fund and well as his extensive philanthropic work in the T1D market environment make him a valuable member of our board of directors.

What is the salary of Sean Doherty?

As the Independent Director of Provention Bio, the total compensation of Sean Doherty at Provention Bio is $725,135. There are 5 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of $3,959,460.

How old is Sean Doherty?

Sean Doherty is 51, he's been the Independent Director of Provention Bio since 2019. There are 9 older and 8 younger executives at Provention Bio. The oldest executive at Provention Bio, Inc. is Avery Catlin, 72, who is the Independent Director.

What's Sean Doherty's mailing address?

Sean's mailing address filed with the SEC is C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK, NJ, 07701.

Insiders trading at Provention Bio

Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski e Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.

What does Provention Bio do?

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Provention Bio executives and stock owners

Provention Bio executives and other stock owners filed with the SEC include:

• Ashleigh Palmer,
  President, Chief Executive Officer, Co-Founder, Director
• Eleanor Ramos,
  Chief Medical Officer
• Francisco Leon,
  Co-Founder, Chief Scientific Officer
• Andrew Drechsler,
  Chief Financial Officer
• Ashleigh W. Palmer B.Sc., M.B.A.,
  Co-Founder, Pres, CEO & Director
• Sean Doherty,
  Independent Director
• Dr. Eleanor L. Ramos,
  Chief Medical Officer
• Dr. Francisco Leon M.D., Ph.D.,
  Co-Founder & Chief Scientific Officer
• Jason Hoitt,
  Chief Commercial Officer
• Andrew T. Drechsler,
  Special Advisor
• Francisco Leon M.D., Ph.D.,
  Co-Founder & Chief Scientific Officer
• Jeffrey Bluestone,
  Director
• Wayne Pisano,
  Independent Chairman of the Board
• Avery Catlin,
  Independent Director
• Sam Martin,
  Investor Relations
• Nancy Wysenski,
  Director
• John Jenkins,
  Director
• Heidy King-Jones,
  Chief Legal Officer
• Jason Hoitt,
  Chief Commercial Officer
• Robert A. Doody Jr.,
  VP of Investor Relations
• Christina Yi,
  Chief Operations Officer
• Thierry Chauche,
  Chief Financial Officer
• Dr. Sherron Kell,
  Sr. VP of Clinical Devel.
• Heidy Abreu King-Jones J.D., L.L.M.,
  Chief Legal Officer
• Justin Vogel,
  Chief Accounting Officer
• Anthony Digiandomenico,
  Director
• Miyoko Christina Yi,
  Chief Operations Officer
• Benedict Osorio,
  Chief Quality Officer
• Thierry Chauche,
  Chief Financial Officer
• Rita Jain,
  Director
• Sarah O'brien,
  Chief People Officer
• Capital (Master), L.P.Sessa...,